Tucson, AZ - Dr. Evan Unger, CEO and Founder of Microvascular Therapeutics (MVT), has been awarded the 2024 Harry Fischer Award by Contrast Media Research (CMR) in recognition of his exceptional contributions to the field of contrast media research. A commemorative medal will be conferred at the annual CMR meeting in October in Oslo, Norway.
Dr. Unger has been at the forefront of ultrasound contrast agent development since 1994. He pioneered the best-selling microbubble contrast agent, Perflutren, and continues to innovate at MVT by creating new and improved contrast agents designed as a platform for theranostic products.
“Thank you to CMR for recognizing my life's work. I am honored to accept this award on behalf of my dedicated team. Their hard work and commitment have been instrumental in our success,” said Dr. Unger. “We have only scratched the surface of what is possible. I am thrilled to leverage my years of experience to advance contrast media and explore new applications in theranostics.”
“This award honors a long-term track record of outstanding research that has significantly shaped the field of contrast media. Specifically, Dr. Unger is recognized for his creative work towards the creation, thorough characterization and demonstration of the feasibility of ultrasound contrast agents in clinical practice”, says Dr. Jeff Bulte on behalf of CMR, who is a Professor of Radiology and Director of Cellular Imaging at the Johns Hopkins University School of Medicine.
Dr. Unger will redirect the monetary sum that comes with this award to support the travel of two junior trainees to attend the CMR meeting.
About Harry Fischer: Dr. Fischer was co-founder of CMR and a pioneer/innovator in the field of X-ray contrast media, clinical translation, safety and expansion of novel uses of contrast media that set the highest standards in the field.
About CMR: Contrast Media Research Symposium (CMR) was initiated by Elliot Lasser, San Diego, and Harry Fischer, Rochester, in 1970 and has had 22 subsequent editions. It has been and continues to be a unique gathering where top-level researchers from academia and the industry meet to exchange up-to-date thoughts and new data in a collegial and open symposium.
About Microvascular Therapeutics (MVT): Microvascular Therapeutics is a clinical-stage biotechnology company based in Tucson, Arizona. As a leader in microbubble and nanobubble technology, MVT is committed to developing the next generation of contrast agents for diagnostic ultrasound. These innovations aim to enhance the diagnosis and treatment of diseases, including vascular diseases and cancer. MVT's new, patented microbubble technology serves as a platform for creating agents for molecular imaging and image-guided therapy. Learn more at www.mvtpharma.com.
Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations as of the date of this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
Commentaires